Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Invalidation Ruling for Evista Upheld: Sawai
November 21, 2016
- Eisai’s BACE Inhibitor Gets FDA’s Fast-Track Status
November 21, 2016
- AbbVie to File for Dual Hep C Treatments Offering Shorter Treatment Time than Harvoni, Sovaldi
November 18, 2016
- Sanofi Begins Praluent Post-Marketing Study in Japanese ACS Patients
November 17, 2016
- Sanofi Japan Looks to Launch 20-Plus Products by 2020: New Chief
November 17, 2016
- Ono Braces for “Unexpected Negative Impact” from Price Cut, Calls for Stable Rules
November 17, 2016
- Japan CNS Market to Reach 648.7 Billion Yen in 2024: Fuji Keizai
November 17, 2016
- First DOAC Antidote to Hit Japan Market This Month
November 16, 2016
- Nipro Pharma Forms Capital Tie-Up with Vietnam’s Mekophar
November 16, 2016
- Sawai Might See Teva-Takeda JV Impact on Distribution Channel: President
November 15, 2016
- Ethical Drug Sales Down 5.6% in September: Crecon Report
November 15, 2016
- Pace of Generic Substitution Slowing at Pharmacies: Sawai President
November 15, 2016
- Regenerative Medicine Market to Expand to 142.1 Billion Yen in 2030: Fuji Keizai
November 11, 2016
- Opdivo Significantly Prolongs OS in Gastric Cancer Patients in PIII Study: Ono
November 11, 2016
- Takecab Most Promoted Drug in September: Anterio
November 11, 2016
- Top 4 Wholesalers See Lower Sales in April-September If Hep C Meds Excluded
November 11, 2016
- Enrollment Completed for PIII Adcetris Study for Mature T-Cell Lymphoma: Takeda
November 10, 2016
- Nippon Shinyaku’s DMD Med Gets Fast Track Status in US
November 10, 2016
- Kipres Generics Earn Bronchial Asthma Indication in Droves
November 10, 2016
- MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
November 10, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…